0001599901FALSE00015999012023-06-152023-06-1500015999012024-06-132024-06-13

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 _________________________________________
FORM 8-K
  _________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): June 13, 2024
  _________________________________________
AVIDITY BIOSCIENCES, INC. 
(Exact name of registrant as specified in its charter)
 _________________________________________
Delaware001-3932146-1336960
(State or other jurisdiction of
incorporation or organization)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
10578 Science Center Drive, Suite 125
San Diego, California 92121 92121
(Address of principal executive offices) (Zip Code)
(858) 401-7900
(Registrant’s telephone number, include area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
 _________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class 
Trading
Symbol(s)
 
Name of each exchange
on which registered
Common Stock, par value $0.0001 per share RNA The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐ 
 
 


 
Item 5.07.Submission of Matters to a Vote of Security Holders.
Avidity Biosciences, Inc., a Delaware corporation (the "Company"), held its 2024 Annual Meeting of Stockholders (the "2024 Annual Meeting") on June 13, 2024. The following is a brief description of each matter voted upon at the 2024 Annual Meeting and the final number of votes cast for, withheld or against, the number of abstentions and the number of broker non votes with respect to each matter, as applicable.

1.    The election of three nominees to serve as Class I directors for a three-year term to expire at the 2027 Annual Meeting of Stockholders. The following three Class I directors were elected by the votes indicated:

ForWithheldBroker Non Votes
Carsten Boess63,891,6289,825,4565,160,086
Sarah Boyce67,562,8736,154,2115,160,086
Troy Wilson, Ph.D., J.D.45,112,98528,048,7385,715,447

2.    The ratification of the appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. The appointment was ratified by the votes indicated:

ForAgainstAbstainBroker Non Votes
78,738,26881,36657,5360

3.    The approval, on an advisory basis, of the compensation of the Company's named executive officers as described in the proxy statement related to the 2024 Annual Meeting. The compensation of the named executive officers was approved, on an advisory basis, by the votes indicated:

ForAgainstAbstainBroker Non Votes
67,573,742995,2075,179,3585,128,863


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
  AVIDITY BIOSCIENCES, INC.
Date: June 14, 2024  By: /s/ Michael F. MacLean
   Michael F. MacLean
   Chief Financial and Chief Business Officer


v3.24.1.1.u2
Cover
Jun. 13, 2024
Jun. 15, 2023
Cover [Abstract]    
Document Type   8-K
Document Period End Date Jun. 13, 2024  
Entity Registrant Name   AVIDITY BIOSCIENCES, INC.
Entity Incorporation, State or Country Code   DE
Entity File Number   001-39321
Entity Tax Identification Number   46-1336960
Entity Address, Address Line One   10578 Science Center Drive
Entity Address, Address Line Two   Suite 125
Entity Address, City or Town   San Diego
Entity Address, State or Province   CA
Entity Address, Postal Zip Code   92121
City Area Code   858
Local Phone Number   401-7900
Written Communications   false
Soliciting Material   false
Pre-commencement Tender Offer   false
Pre-commencement Issuer Tender Offer   false
Title of 12(b) Security   Common Stock, par value $0.0001 per share
Trading Symbol   RNA
Security Exchange Name   NASDAQ
Entity Emerging Growth Company   false
Entity Central Index Key   0001599901
Amendment Flag   false
Avidity Biosciences (NASDAQ:RNA)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas Avidity Biosciences.
Avidity Biosciences (NASDAQ:RNA)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas Avidity Biosciences.